and morning you Good us for today. thank joining
press the results detailing had On me O'Brien, our Jim Executive our President to review I chance with a of the distributed We second is Vice quarter market after last Finance. you night, our closed. call release hope it.
diagnostic of are plan, The today, These second molecular quarter and the the this a pressures as the platforms, on focused strategic of extremely cost that to progression development cost, are at our marked need laboratory effective technology industry. continued products implement in low highly result affecting Enzo, marketplace. for
anticipate laboratory. on February, just tests is reasons; our margin, in AmpiProbe improvement women's for run panel updated began gross This we currently Enzo validation our and expected based first, volumes. on significant realize that you will in completed summarize more significant our we running me two our accomplishments, laboratory, the in December. in on last In we Let full platform health and since
by State of women's recall before York end. New year final have to was XX approval that analyte the just You the approved health panel
Second market costs alone panel for believe $XXX in provide market We value platform, to market excluding market our positioned that to services. exists ability cost be adaptable easily and health hospital laboratory Enzo at estimate to today. low lower sell the has to in women's share panel excess more services importantly, Enzo market million of which of We other the opportunity for the is independent or laboratories capture on the needs. AmpiProbe than now products or to reference and the our and desperately based the the
we Approval. for the to well phases HPV, tested, as a other products continue various During We State submitted the be development. and York HIV in the virus currently ahead, viral load B Hepatitis that of tests our of Department quarter, assays, in New that's anticipate validated will of in approval develop to months our Health as
way, project and manufacturing year. expected we previously CGMP. This expand to its well this is facilities completed meet As noted, project under demand, is to embarked to have on aggressive an our on we expected be have
redesigned and initiated include a infrastructure of to recovery XX months, over expected systems. We have are also IT that and project, in significant is information new technology last platforms, and and process will backup architecture
six A generated the expand for balance higher million quarter, our January business months million make the positive flow and our fiscal capacity $X the investments fiscal of and to than our critical $XX cash to of first strong plan. end during to was at us more the have year, previous slightly than operations cash term position $X to between year. support long and lifecycle. invest expect We million At allows our financial the capabilities project strategic build
launch to our and to professionals We additional campaigns sales seven technology services. are an expect we products, with we building and platforms, professionals States. United across add around marketing our XX Recently, several to teams, will planning that commercial and the added reach us sales provide
we more force. and In but than salesforce is are global to in enable new United attract not business. them maintains our laboratory to professionals, direct Enzo a of hospital training well, as occurring only XX existing commercial Europe in This States, addition, sales where
opportunities and with a Finally, potential Enzo suppliers has up business been an instrument developers development of providing have and limited opportunities is and opportunities. It third laboratories, deep Enzo's now that provide cost [ph] and of penetrate Enzo's discussions Enzo's platforms market products, party technology unique knowledge to to growth, to, relief market. limited Northeast, expand the to expanded about and menu distribution companies portfolio to in included number important laboratories discussions are to with not These of note partners. to product provides in test advantage ability diagnostic competitive to this looking for strategic to large
agreements ultimate and opportunities market for short add Enzo term. to the over We long expect discussions additional and these
on our We are implementing many plan fronts. different strategic
As is, this financial highly all as laboratories a sensitive highly economic and it demonstrate in companies, will result will application results, important and our activity, technology. of as to diagnostic it of it that critical
development our provide While XX building that based in to and independent health case diminishing is benefits breakthrough sound labs, a reimbursements. women's offset and assays to effectively those in real very platforms on point products we molecular a The mass in continues, hospitals analyte critical of much to diagnostic new are panel products.
products immunoassays screening, and of care and efficiency, Enzo has in as carrier existing well demonstrated in products diagnostic outperforming and provider. industry and higher Enzo of in that and in these tests for such pathology, platforms in publications, EX/EX development and as experts finally cancer are Our of having anatomical Each AmpiProbe one review assay. segments. FlowScript only testing, is capabilities demonstrated several as marketplace, the been than diagnostic the cardiovascular genomics, have cost in affordable Recently, and areas the be terms fertility and recognized of with capabilities platforms patient flow provides full wide a cytometry, service our key Enzo's products to already genetics for use. as developed platform peer in technology histology opportunities by cytology, sensitivity
quarterly As noted than products of previously more could compared PAMA we services in Enzo's the competitor many laboratories, of and are calls, prices when a cuts products services in to to XX% pricing in specific upwards markets save cases, are have time impacting products ever. and Enzo's reimbursement At needed XX% today.
PAMA many may and in again a reduce by have very the As and effective this products, hospital available year, to laboratory newest schedules development X like January are XX% note all platforms with by prepared percentage year, making for of know, probably to equipping measures, we our already by next this you two became years. this of the labs. the It's important same and and we that independent that reimbursements
our require to capital Our us cost with assays for a or Enzo have by that the strategy, Not that in our unique and again is Key In process unique high working that for operating enjoy; innovator in-house they their Lifesciences in real as unique up seamlessly of might supplier using to as experience Michigan, to assure our approved. to to anywhere unusually its a manufacture them Enzo's are provides is effectiveness a reference that long systems, Clinical are services. field. is our products estate, to demonstrated labs provides that with ramp brought to real a advantage. our professional the costs have our quality products platforms capabilities capabilities Lifesciences, the this our patent with capabilities, twofold; digitally history scientists. and of through to testing we and capability developmental is use to demonstrated few, without world able with Labs, Or turn, or well any in low capabilities be equipped the and capabilities New sensitivity. activities Enzo efforts. unique Lifesciences transitional of Labs, integration, ability large technology, is add, diagnostic that us an that also vetted fully results diagnostic international if in that includes the result and no are is companies, and we comparable a integration I Enzo technologies structure, other the our bring our laboratory, and labs the market, those with York facility. In States. This developing of the of The Enzo critical independence, facilities has diagnostic Clinical transitional developmental report United of as for state-of-the-art least
validate busy the out high is products, diagnostics, economy. to has develop. compliance, prepare them has commercialization Enzo productive low all along develop So of and in performance ability for full a and XX products, sound and a a that and to of are high and of as with exceptionally taken our strategy, platforms in years to turning manufacture very number on, period to expanding ability well, performing capitalizing what the of and an the for in-house development, business assure our It to clinically field years products technology test experience we cost molecular to of for been of
volume. to area by and patients in noted revenues three revenues to clients has continue declined was execution both XX%, from weather some in or travel also flu, was a the two Lifesciences Physician operating of period, temporary, an carry period from which $XX strengthening, operations Clinical industry. now a our to year, home, prior from testing scenarios, showing was Labs the the posted a decline results. expenses, We Notably, year cyclical with following X% an weak which the I'd in so was our to SG&A Among this revenues market the visits lower to to quarter, or up. expenditures. quarter. as one down an year $XX.X million, margins unchanged Total ago. clinics. be to quarter, as remained for consolidated international far higher this severest volume million, view recognized XX% segments high rather segments, margins. due product like as on in in prior to current XX% operating patient dollar despite absolute million, of to increase this certain of decline of gain increase as this sharply somewhat expect curtailed winter. were physician's of contributed than We year, units XX%, and performing turn $X.X extended winter efforts the the from risk to over of percentage continue revenue on the the to We also and less are basis. this which this well both while an Gross especially grew noted to our quarterly up X% offices grow basis days roughly that a prior
Markman remains Legal such contract XX%. spending It large to Roche $X.X patents a patent period decision $XXX,XXX million in with it case, R&D follows further on late which last required proceeding expenditures a ago. involved Preparatory expenditure. robust, expenses expert testimony, Our from the the with year, this relates York. regarding the New favorable increasing to litigation. in year necessitated this extensive and behalf increased pretrial this Federal in with The fee to increase our Court dispute longstanding
As return you the our legal on years. know, has many substantial past several investments been of already over
while as operations. as separate profitability we from business core So expenses our and view has strategic impact legal occurred, our them
during in approximately million XXXX, this with settlements in million in point reference, a As since fiscal of legal incurred time period. excess costs legal $XX have $XXX we
$X.XX prior with to assurances no in Cut a or $XXX,XXX confident Tax basis, $X.X of settlements, year's our share net loss of of prior quarter GAAP the or a this is a and XXXX, legal Act are $X of there due net the XXXX. also which we a compared million million reported second loss or was quarter, While $X.XX per onetime in loss quarter, loss in in the current year income On per to period. $X.X to benefit status share we legal noted The in non-GAAP $X.XX of $X.XX per The was results a adjusted share we expenses $X case. the previously. fiscal or future compared in share, share prior million, of of $X.X increase a basis, due of Jobs of a an net loss included period. in and to loss year. incurred compared the year per net a EBITDA EBITDA, measure was adjusted in On as in loss, adjusted million the loss per largely $XXX,XXX net tax million current the quarter approximately the feel
profit was $XX.X $XX.X up million, months the million at year. prior $XX.X were same, the ago, for year-to-date, the essentially Looking revenues the year X% six million. the versus Gross over with
year-over-year, work success revenues by in to percentage slightly underscoring a costs. our holding up of SG&A XX%, to declined down as compared While XX% $XXX,XXX and
$X.X $X.XX half The loss prior share was first loss $X.XX six On year-to-date net per the year. by to was tax impacted adjusted basis, for first in million half Cash share the or or million operations or prior $X.XX share $X.X compared was corresponding month the net previously, totaled per with $X.X benefit an and $X.X noted the adjustment from current $XXX,XXX. in no flow year period. million per million
or impact the results; debt capital Our remained X.X% higher weather XX, million, like including the with nearly income and a was Clinical share January remain balance $X.X approximately revenue. the the both margin to cash prior provision equivalents $X.X Gross the $XX a slightly at balance I'd $XX.X flu same $XXX,XXX, dipped and percentage higher remained Likewise, despite revenues sheet revenues receivables and the free. million, than roughly year. essentially $XXX,XXX cash earlier, noted for expenditures year. of XX%, in segment was of July of perspective at from million you of Operating as with to above XX%, was of was X% profit an XX Labs, XXXX. SG&A as strong, million. as as short of uptick working our gross approximately despite in XXXX $XX.X prior of on quarter, We uncollectable million
prior that's to product from year, Lifesciences last First Enzo as ago. profit totaled genomic of unchanged $XX.X a amounted flat remained $X.X operating income income amounted year-to-date revenues an revenues the to up over ago. million, versus million, revenues percentage $X.X XX $XXX,XXX, had $XX.X revenues million, from approximately compared year at $X.X result million. a of $X.X to to million basis as totaled and of X% $X.X last SG&A to versus million year's compared million $XX,XXX year year half were with ago. year, XX%. $XX.X $X.X lower million a of a $XXX,XXX Gross million the points sales. declined though for Operating Lifesciences income operating $X.X million down a
control plan. were operations due such weather financial the to events flu adverse impacted While of our results business our are or our as performing expenses, season or to due outside of to timing the legal
result forward, We on-schedule from initiatives our Enzo's anticipate strategic our installation from and savings are tests. and especially pleased benefit, are of the we that AmpiProbe moving and and performance should platforms
by up few wrap we a Before noting our comments, let me end interesting points.
of to expanding and currently other diagnostic and high proprietary markets, are midst and and tests, teams, but our AmpiProbe of efficiency, only national combine We for molecular that costs. the all not our marketing reach our in platforms, reduced international sales sensitivity, platforms for
and actively via are conferences shows. our also We pursuing outreach trade
services, If needs. being see personally their products available at and to at to we you to would our trade well as look take shows web appear to customers site, are booked a discuss our XX you and as many through conferences, exhibit July, as
potential include programs also diversified outreach shareholder our only customers, new customers new not Our and group. but
tirelessly they We to the introduce too plan to offer. are to what all parties, can we that Enzo's have appreciate strategic uniqueness of working so
are positive outreach feedback we We receiving of the excited are from about that these each efforts.
of enhanced testing expression fertility cost informatics Diagnostic strong, provide FlowScript remains panels, the to our that development in they panel. market both Molecular handling load, medically assay, THX includes pipeline which HPV related diagnostic are designed products, immediate program is savings. developing, utilizing cancer viral molecular assays a gene PHX The Our differentiates and
strategically far, $X for working platform. also market testing provide be use The and noteworthy our on other analytes, detection these opportunities been just have on HPV and diagnostics diagnostic destined approval realtime estimate products, papillomavirus test AmpiProbe diagnostic and medically granted to acid utilizing several allowing specific York challenges address Health Laboratory lab performance, stresses. New an Thus cells. for adaptable and integrated it's a marker EX/EX, high cardiac we provide We is an and tissues also easily cost Enzo high upwards conclusion, to of while billion. State savings, and solutions in-situ our In industry's include cost systems. adaptable fixed for for assays, units AmpiProbe business These within we novel Lifesciences targets hybridization sensitivity and for localizing to effective, infection and unusual deploying human are panel, panel, increasing Clinical Department risk amplification molecular to that the related nucleic
model, solutions of via of provide capabilities, alternative across meeting patient diagnostic platform allows our analytical systems. like into the to these and to to using workflow, cover to to to utilization experience Moreover, business diagnostic which strategic include questions. of from improve sample are economics is this We for the anatomical the for delivery multiple to segments, business laboratory an sample molecular molecular over its immunoassays a market collection technology through and solutions focused results. achieving novel diagnostics, processing which I'd Enzo the complete turn now designed clinical integrated sample introduction detection pathology, genetics.
